A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
Inclusion criteria:
Exclusion criteria:
CABA, Buenos Aires C1122AAF, Argentina
CABA, Buenos Aires C1181ACH, Argentina
CABA, Buenos Aires C1425AWC, Argentina
Inashiki-gun, Ibaraki 300-0395, Japan
Bunkyo-ku, Tokyo 113-8655, Japan
Chiyoda-ku, Tokyo 102-8798, Japan
Minato-ku, Tokyo 105-8471, Japan
Shinagawa-ku, Tokyo 141-8625, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Shinjuku-ku, Tokyo 160-8582, Japan